Roche
F. Hoffmann-La Roche AG is a Swiss multinational healthcare enterprise that discovers, develops, and manufactures innovative pharmaceuticals and diagnostic instruments worldwide. The company conducts its operational activities through two primary business divisions: Pharmaceuticals and Diagnostics. Its commercial product portfolio includes market-leading biopharmaceutical therapeutics for oncology, immunology, ophthalmology, and neuroscience, alongside automated in vitro diagnostic systems and PCR testing kits. Principal revenue drivers consist of global commercial sales of proprietary prescription biopharmaceuticals, such as Ocrevus, Hemlibra, and Perjeta, complemented by diagnostic equipment and assay kit sales. Roche serves diverse healthcare end markets including hospital networks, clinical laboratories, pathology centers, medical specialists, and patients across more than one hundred countries. The enterprise holds a dominant global market position as the world's largest provider of oncology medicines and a premier provider of in vitro diagnostics. Headquartered in Basel, Switzerland, the company's non-voting equity securities are primary listed on the SIX Swiss Exchange under ticker symbol ROG and trade globally.
156 of the funds FundTelligence covers report a position in Roche.
- Sector
- Health Care
- Country
- Switzerland
- Funds holding it
- 156
- Exposure themes
- Cancer, Diagnostics and screening, Prevention, Treatment, Women's Health
Funds holding Roche
- BlackRock iShares MSCI Europe Health Care Sector UCITS ETF — BlackRock · 17.67 % (full portfolio disclosed, October 2026)
- Fidelity Switzerland Fund — Fidelity · 9.8 % (largest positions only, October 2026)
- DNB Health Care — DNB · 6.94 % (full portfolio disclosed, September 2026)
- Fondsfinans Global Helse — Fondsfinans · 6.65 % (full portfolio disclosed, October 2026)
- Fidelity Global Healthcare Fund — Fidelity · 6.1 % (largest positions only, October 2026)
- AB International Health Care Portfolio — AllianceBernstein · 5.72 % (largest positions only, September 2026)
- Fidelity Europe Equity ESG Fund — Fidelity · 5.2 % (largest positions only, October 2026)
- DNB Fund Women's Health — DNB · 5.16 % (full portfolio disclosed, August 2026)
Showing the 8 largest of 156 funds holding it.